维多利祖马布
纳塔利祖玛
医学
炎症性肠病
溃疡性结肠炎
免疫学
归巢(生物学)
淋巴细胞
疾病
内科学
生态学
生物
多发性硬化
作者
Masayuki Saruta,Konstantinos A. Papadakis
标识
DOI:10.1016/j.gtc.2014.05.012
摘要
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.
科研通智能强力驱动
Strongly Powered by AbleSci AI